Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making

Charles A. Clark, Robert F. Cornell, Emma Scott, Jae Chung, Luciano J. Costa

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Although upfront treatment of multiple myeloma has become more effective, relapses are the norm, often driven by the emergence of a genetically divergent clone selected by the initial therapy. Recent trials have demonstrated the safety and efficacy of combination therapy also in the relapsed and refractory setting and supported the regulatory approval of several new agents including new proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. We provide a detailed summary of recent practice-changing trials in relapsed and refractory MM and share a practical approach to assimilate disease and patient-features into treatment decision. Am. J. Hematol. 91:1044–1051, 2016.

Original languageEnglish (US)
Pages (from-to)1044-1051
Number of pages8
JournalAmerican Journal of Hematology
Volume91
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Multiple Myeloma
Decision Making
Proteasome Inhibitors
Therapeutics
Clone Cells
Monoclonal Antibodies
Safety
Recurrence

ASJC Scopus subject areas

  • Hematology

Cite this

Management of relapsed and refractory multiple myeloma in modern times : Incorporating new agents into decision-making. / Clark, Charles A.; Cornell, Robert F.; Scott, Emma; Chung, Jae; Costa, Luciano J.

In: American Journal of Hematology, Vol. 91, No. 10, 01.10.2016, p. 1044-1051.

Research output: Contribution to journalReview article

Clark, Charles A. ; Cornell, Robert F. ; Scott, Emma ; Chung, Jae ; Costa, Luciano J. / Management of relapsed and refractory multiple myeloma in modern times : Incorporating new agents into decision-making. In: American Journal of Hematology. 2016 ; Vol. 91, No. 10. pp. 1044-1051.
@article{216eadba603b4e84a143bb15325ee95a,
title = "Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making",
abstract = "Although upfront treatment of multiple myeloma has become more effective, relapses are the norm, often driven by the emergence of a genetically divergent clone selected by the initial therapy. Recent trials have demonstrated the safety and efficacy of combination therapy also in the relapsed and refractory setting and supported the regulatory approval of several new agents including new proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. We provide a detailed summary of recent practice-changing trials in relapsed and refractory MM and share a practical approach to assimilate disease and patient-features into treatment decision. Am. J. Hematol. 91:1044–1051, 2016.",
author = "Clark, {Charles A.} and Cornell, {Robert F.} and Emma Scott and Jae Chung and Costa, {Luciano J.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1002/ajh.24478",
language = "English (US)",
volume = "91",
pages = "1044--1051",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Management of relapsed and refractory multiple myeloma in modern times

T2 - Incorporating new agents into decision-making

AU - Clark, Charles A.

AU - Cornell, Robert F.

AU - Scott, Emma

AU - Chung, Jae

AU - Costa, Luciano J.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Although upfront treatment of multiple myeloma has become more effective, relapses are the norm, often driven by the emergence of a genetically divergent clone selected by the initial therapy. Recent trials have demonstrated the safety and efficacy of combination therapy also in the relapsed and refractory setting and supported the regulatory approval of several new agents including new proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. We provide a detailed summary of recent practice-changing trials in relapsed and refractory MM and share a practical approach to assimilate disease and patient-features into treatment decision. Am. J. Hematol. 91:1044–1051, 2016.

AB - Although upfront treatment of multiple myeloma has become more effective, relapses are the norm, often driven by the emergence of a genetically divergent clone selected by the initial therapy. Recent trials have demonstrated the safety and efficacy of combination therapy also in the relapsed and refractory setting and supported the regulatory approval of several new agents including new proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. We provide a detailed summary of recent practice-changing trials in relapsed and refractory MM and share a practical approach to assimilate disease and patient-features into treatment decision. Am. J. Hematol. 91:1044–1051, 2016.

UR - http://www.scopus.com/inward/record.url?scp=84990223466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990223466&partnerID=8YFLogxK

U2 - 10.1002/ajh.24478

DO - 10.1002/ajh.24478

M3 - Review article

C2 - 27415608

AN - SCOPUS:84990223466

VL - 91

SP - 1044

EP - 1051

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 10

ER -